Peripheral Arterial Diseases Clinical Trial
Official title:
Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent With Delivery System -The SUMMIT Registry
The intent of this clinical registry is to demonstrate the efficacy of the EPIC™ stent in
patients with superficial femoral/ popliteal artery disease.
100 patients with symptomatic femoropopliteal artery lesion will be enrolled in the study
and shall undergo 4 visits during the trial -a pre-procedure visit, procedure visit at which
time the stent will be placed, and follow-up visits at 6 and 12 months.
Study hypothesis: The EPIC™ Self-Expanding Nitinol Vascular Stent with Delivery System will
be efficacious in patients with Superficial Femoro/Popliteal Artery disease.
The SUMMIT Registry addresses the treatment of peripheral arterial disease (PAD).
PAD represents a major challenge to physicians in treating the Superficial Femoral (SFA) and
Popliteal arteries. These vessels are exposed to enormous mechanical stress what represents
a harsh environment for any endovascular device. During flexing of the knee, the
SFA/Popliteal arteries can bend, rotate, elongate and compress dramatically. An ideal stent
designed for use in the SFA/Popliteal arteries would offer great ranges of movement while
adequately supporting the arteries.
Subject of study is the EPIC™ Femoropopliteal Self-Expanding Stent System which provides a
great range of motions for a highly flexible femoral artery while adequately supporting the
vessel.
Primary objective is to evaluate the efficacy of the device in treating lesions of the
SFA/Popliteal artery.
The project is a multi-centre open label study. Primary efficacy parameter will be assessed
by measuring the in-stent binary stenosis using duplex ultrasound at 6 and 12 months after
the stent placement. Binary restenosis is defined as a peak systolic velocity ratio (PSVR)
≥2.5:1.
Anticipated study duration is 18 months: 6 months recruiting and 12 months follow-up.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02041169 -
Lower Extremity Peripheral Arterial Disease and Exercise Ischemia
|
N/A | |
| Completed |
NCT01436435 -
The Jetstream (JET) Post-market Registry
|
Phase 4 | |
| Completed |
NCT01983449 -
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
|
Phase 4 | |
| Completed |
NCT03469349 -
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
|
Phase 3 | |
| Completed |
NCT00640770 -
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease
|
Phase 4 | |
| Recruiting |
NCT05192707 -
Transcutaneous Oxygen Pressure (TcPO2) Determination.
|
||
| Withdrawn |
NCT02531139 -
The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery
|
N/A | |
| Completed |
NCT00652418 -
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
|
Phase 2 | |
| Completed |
NCT02920125 -
Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.
|
Phase 3 | |
| Completed |
NCT02273232 -
Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial
|
Phase 1 | |
| Completed |
NCT01952756 -
Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
|
Phase 4 | |
| Completed |
NCT01419418 -
Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes
|
N/A | |
| Completed |
NCT02066740 -
EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study
|
N/A |